What Is Happening in Drug Discovery?
The integration of artificial intelligence (AI) into drug discovery is reshaping pharmaceutical development, prompting regulatory bodies to adapt their frameworks
The Art of "Building" a VC Track Record: How to Be Economical With the Truth
Venture capital, like any industry where past success is difficult to verify, has a long tradition of being economical with
The “Game-Changing” Illusion: How Pharma Spins Mediocre Drugs Into Miracles
Every year, the pharma industry rolls out its latest batch of “game-changing,” “best-in-class,” and “first-in-class” therapies, showering them with press
Venture Debt: A Deal With the Devil You Know
capable of wreaking havoc if overindulged. For biotech founders staring down the barrel of cash burn and trial delays, it
The Real-World Impacts of Neglecting Extreme Value Theory (EVT) in Biotech and Pharma
Focusing on the real-world impacts of neglecting Extreme Value Theory (EVT), particularly in biotechnology and pharmaceuticals, offers a potent narrative.
Decoding Kaplan-Meier Survival Analysis: A Critical Examination of Its Use and Misuse in Cancer Trials
The biotech world thrives on optimism. Pitch decks brimming with breakthroughs and life-saving treatments are a staple of the industry’
The problem with POPT
The Problem with Probability of Phase Transition (POPT) in Biotech and Pharma
Probability of Phase Transition (POPT) is a commonly
Case Studies: Failures Due to Ignoring Fat Tails in Biotech Investments
Biotech investments are uniquely characterized by uncertainty, where extreme events—whether unexpected breakthroughs or catastrophic failures—play an outsized role.
The Great Innovation Theater: Why (Most) Corporate Accelerators Are Just PR on a Budget
Every year, large corporations—especially in pharma and biotech—proudly announce new startup accelerators, innovation challenges, or early-stage grant programs
Unveiling the Limitations of Survival Analysis: A Closer Look at Hazard Ratios, Cumulative Incidence, and RMST
Hazard ratios (HRs) are a widely used measure in survival analysis, summarizing the relative risk of an event occurring in
